A potent GHRH analog available in short-acting and long-acting forms — one of the most prescribed GH secretagogues.
CJC-1295 refers to a family of synthetic GHRH analogs. The original CJC-1295 contains a Drug Affinity Complex (DAC) — a chemical modification that binds albumin in the bloodstream, dramatically extending the half-life to approximately 6–8 days. This allows much less frequent dosing (once or twice weekly versus daily).
CJC-1295 without DAC is chemically identical to Modified GRF (1-29) — a stabilized version of the first 29 amino acids of GHRH, similar to sermorelin but with 4 amino acid substitutions that increase stability and potency. Without DAC, the half-life is approximately 30 minutes, producing more physiological pulsatile GH release. Many providers now prefer 'no DAC' for this reason.
CJC-1295 (in both forms) is widely combined with ipamorelin, a complementary GHRP, for synergistic GH stimulation. This combination is one of the most commonly prescribed peptide protocols in regenerative and anti-aging medicine. It is not FDA-approved for any indication.
Clinical studies on CJC-1295 with DAC showed dose-dependent increases in GH and IGF-1 levels lasting days after a single injection (PMID: 16882916). Preclinical and early clinical work demonstrates the expected physiological effects of elevated GH: increased IGF-1, improved body composition, enhanced recovery.
The combination of GHRH analogs with GHRPs (like ipamorelin) has been shown to produce synergistic GH release — greater than either agent alone. This combination approach is the basis of most clinical protocols.
📚 Key Reference: PMID: 16882916 (CJC-1295 with DAC pharmacokinetics)
Generally well-tolerated at clinical doses. Most common side effects: injection site reactions, water retention, headache, and transient tingling/numbness. Excessive GH stimulation can cause joint pain, carpal tunnel syndrome, and glucose intolerance. Regular IGF-1 monitoring is essential to avoid over-dosing. Contraindicated with active cancer. Consult your provider.
Not FDA-approved for any indication. Available through compounding pharmacies. Classified as research-grade in many jurisdictions. WADA (World Anti-Doping Agency) prohibits its use in competitive sport. Legal status for prescription compounding under medical supervision is generally maintained in the US.